
-
Leap Therapeutics NasdaqCM:LPTX Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Location: 47 Thorndike Street, Cambridge, MA, 02141, United States | Website: https://www.leaptx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-31.51M
Cash
47.25M
Avg Qtr Burn
-15.07M
Short % of Float
6.89%
Insider Ownership
3.37%
Institutional Own.
49.32%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Sirexatamab (DKN-01) + Pembrolizumab Details Cancer, Endometrial cancer | Phase 2 Data readout | |
Sirexatamab (DKN-01) + Bevacizumab and Chemotherapy Details Advanced microsatellite stable colorectal cancer | Phase 2 Update | |
Sirexatamab (DKN-01) +/- Paclitaxel Details Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer | Phase 2 Update | |
FL-301 Details Cancer, Pancreatic cancer, Gastric cancer | Phase 1 Data readout | |
Sirexatamab (DKN-01) +/- Docetaxel Details Prostate cancer | Failed Discontinued | |
Sirexatamab (DKN-01) + Tislelizumab +/- CAPOX Details Gastroesophageal junction tumors, Cancer, Gastric cancer | Failed Discontinued |